VXRT

insider transactions

Vaxart, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

+10.0K

10.0K buy · 0 sell

Net value · 365d

$6.5K

$6.5K in · $0 out

Sentiment · 365d

Net buying

100% buying · 0% selling

Open-market trades · 365d

10.0K buy · 0 sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Buy·P
May 22, 26

Mark W. Watson

Director

$6.5K

10.0K sh · $0.65

Own +8%
Other·F
May 19, 26

Jeroen Nicolaas Grasman KEY

Chief Financial Officer

$19.2K

31.4K sh · $0.61

Own -5%
Grant·A
Apr 23, 26

James B Breitmeyer

Director

$0

157.4K sh

Own New
Grant·A
Apr 23, 26

James B Breitmeyer

Director

$0

78.8K sh

Own New
Other·F
Mar 28, 26

Sean Tucker

SVP, Chief Scientific Officer

$2.6K

3.9K sh · $0.65

Own -0%
Other·F
Mar 28, 26

James F. Cummings

Chief Medical Officer

$2.1K

3.3K sh · $0.65

Own -0%
Other·F
Mar 24, 26

Sean Tucker

SVP, Chief Scientific Officer

$25.3K

36.4K sh · $0.69

Own -4%
Other·F
Mar 24, 26

Steven Lo KEY

President, Chief Exec Officer

$87.5K

126.0K sh · $0.69

Own -5%
Other·F
Mar 24, 26

James F. Cummings

Chief Medical Officer

$21.2K

30.6K sh · $0.69

Own -3%
Other·F
Mar 24, 26

Edward B Berg

SVP, General Counsel

$25.3K

36.4K sh · $0.69

Own -5%
Other·F
Mar 18, 26

Sean Tucker

SVP, Chief Scientific Officer

$5.1K

8.1K sh · $0.63

Own -1%
Other·F
Mar 18, 26

Steven Lo KEY

President, Chief Exec Officer

$14.2K

22.4K sh · $0.63

Own -1%
Other·F
Mar 18, 26

James F. Cummings

Chief Medical Officer

$4.3K

6.8K sh · $0.63

Own -1%
Other·F
Mar 18, 26

Edward B Berg

SVP, General Counsel

$5.1K

8.1K sh · $0.63

Own -1%
Grant·A
Mar 16, 26

Sean Tucker

SVP, Chief Scientific Officer

$0

410.0K sh

Own New
Grant·A
Mar 16, 26

Sean Tucker

SVP, Chief Scientific Officer

$0

200.0K sh

Own +27%
Grant·A
Mar 16, 26

Steven Lo KEY

President, Chief Exec Officer

$0

1.5M sh

Own New
Grant·A
Mar 16, 26

Steven Lo KEY

President, Chief Exec Officer

$0

846.5K sh

Own +47%
Grant·A
Mar 16, 26

Jeroen Nicolaas Grasman KEY

Chief Financial Officer

$0

455.0K sh

Own New
Grant·A
Mar 16, 26

Jeroen Nicolaas Grasman KEY

Chief Financial Officer

$0

227.0K sh

Own +65%
Grant·A
Mar 16, 26

James F. Cummings

Chief Medical Officer

$0

455.0K sh

Own New
Grant·A
Mar 16, 26

James F. Cummings

Chief Medical Officer

$0

227.0K sh

Own +31%
Grant·A
Mar 16, 26

Edward B Berg

SVP, General Counsel

$0

225.0K sh

Own New
Grant·A
Mar 16, 26

Edward B Berg

SVP, General Counsel

$0

115.0K sh

Own +17%
Other·F
Feb 2, 26

Sean Tucker

SVP, Chief Scientific Officer

$5.6K

9.3K sh · $0.61

Own -1%
Other·F
Feb 2, 26

James F. Cummings

Chief Medical Officer

$4.8K

8.0K sh · $0.61

Own -1%
Other·F
Feb 2, 26

Edward B Berg

SVP, General Counsel

$5.6K

9.3K sh · $0.61

Own -1%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
May 22, 2026	Mark W. Watson	Director	Buy P	10.0K	+8%	$0.65	$6.5K
May 19, 2026	Jeroen Nicolaas Grasman KEY	Chief Financial Officer	Other F	31.4K	-5%	$0.61	$19.2K
Apr 23, 2026	James B Breitmeyer	Director	Grant A	157.4K	New	—	$0
Apr 23, 2026	James B Breitmeyer	Director	Grant A	78.8K	New	—	$0
Mar 28, 2026	Sean Tucker	SVP, Chief Scientific Officer	Other F	3.9K	-0%	$0.65	$2.6K
Mar 28, 2026	James F. Cummings	Chief Medical Officer	Other F	3.3K	-0%	$0.65	$2.1K
Mar 24, 2026	Sean Tucker	SVP, Chief Scientific Officer	Other F	36.4K	-4%	$0.69	$25.3K
Mar 24, 2026	Steven Lo KEY	President, Chief Exec Officer	Other F	126.0K	-5%	$0.69	$87.5K
Mar 24, 2026	James F. Cummings	Chief Medical Officer	Other F	30.6K	-3%	$0.69	$21.2K
Mar 24, 2026	Edward B Berg	SVP, General Counsel	Other F	36.4K	-5%	$0.69	$25.3K
Mar 18, 2026	Sean Tucker	SVP, Chief Scientific Officer	Other F	8.1K	-1%	$0.63	$5.1K
Mar 18, 2026	Steven Lo KEY	President, Chief Exec Officer	Other F	22.4K	-1%	$0.63	$14.2K
Mar 18, 2026	James F. Cummings	Chief Medical Officer	Other F	6.8K	-1%	$0.63	$4.3K
Mar 18, 2026	Edward B Berg	SVP, General Counsel	Other F	8.1K	-1%	$0.63	$5.1K
Mar 16, 2026	Sean Tucker	SVP, Chief Scientific Officer	Grant A	410.0K	New	—	$0
Mar 16, 2026	Sean Tucker	SVP, Chief Scientific Officer	Grant A	200.0K	+27%	—	$0
Mar 16, 2026	Steven Lo KEY	President, Chief Exec Officer	Grant A	1.5M	New	—	$0
Mar 16, 2026	Steven Lo KEY	President, Chief Exec Officer	Grant A	846.5K	+47%	—	$0
Mar 16, 2026	Jeroen Nicolaas Grasman KEY	Chief Financial Officer	Grant A	455.0K	New	—	$0
Mar 16, 2026	Jeroen Nicolaas Grasman KEY	Chief Financial Officer	Grant A	227.0K	+65%	—	$0
Mar 16, 2026	James F. Cummings	Chief Medical Officer	Grant A	455.0K	New	—	$0
Mar 16, 2026	James F. Cummings	Chief Medical Officer	Grant A	227.0K	+31%	—	$0
Mar 16, 2026	Edward B Berg	SVP, General Counsel	Grant A	225.0K	New	—	$0
Mar 16, 2026	Edward B Berg	SVP, General Counsel	Grant A	115.0K	+17%	—	$0
Feb 2, 2026	Sean Tucker	SVP, Chief Scientific Officer	Other F	9.3K	-1%	$0.61	$5.6K
Feb 2, 2026	James F. Cummings	Chief Medical Officer	Other F	8.0K	-1%	$0.61	$4.8K
Feb 2, 2026	Edward B Berg	SVP, General Counsel	Other F	9.3K	-1%	$0.61	$5.6K

About VXRT insider trading

This page tracks insider transactions for Vaxart, Inc. (VXRT) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.